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8.1 Introduction
With the implementation of the Medicare Modernization Act in 2006,
the federal government became responsible for the ﬁnancing of prescrip-
tion drugs for all Medicare recipients. Though there have been several at-
tempts to forecast how much ﬁnancial risk will be borne by the government
in future years as a consequence of the introduction of Medicare Part D,
no forecast has separately analyzed the eﬀect of disability on Part D spend-
ing. This is unfortunate because the disabled elderly are among the groups
that might be most aﬀected by pharmaceutical innovations and changes in
the way prescription drugs are ﬁnanced. They use health services heavily,
visit physicians more frequently, enter the hospital more often, and use
long-term care more heavily than the nondisabled. It is likely that the same
is true of their consumption of prescription drugs, although usage of med-
ications has not been studied nearly as extensively as the use of products
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tance of Tikhon Bernstam and Grecia Marrufo.and services that Medicare traditionally covered. Similarly, there has been
little work examining the patterns of pharmaceutical use by individuals un-
der sixty-ﬁve who qualify for Medicare through the Disability Insurance.
In this paper, we use the Medicare Current Beneﬁciary Survey (MCBS)
to analyze trends in the utilization of pharmaceuticals by disabled and
nondisabled beneﬁciaries in the community (noninstitutionalized) be-
tween 1992 and 2001. We examine both the over-sixty-ﬁve population and
the population under sixty-ﬁve that qualiﬁes for Medicare by virtue of
their disability. We compare the rates of growth of prescription drug use in
these two groups, along with changes in the share of medical expenditures
attributable to prescription drugs. We examine both overall prescription
drug uses and use by class. We then discuss the implications of changing
disability rates for drug beneﬁts and for overall health care expenditures.
8.2 Background
Providing medical care for the disabled is expensive, and pharmaceuti-
cal products account for a nontrivial fraction of that expense. In recent
years, disability prevalence among elderly and near-elderly populations
has been changing dramatically, but in opposite directions. In this section,
we review these changes, and argue that the implementation of the Medi-
care drug beneﬁt greatly increases the importance of this debate.
There is broad literature documenting trends in disability in the elderly
population. In the past two decades, much support can be found for the
hypothesis that active life span is increasing faster than total life span—see
Fries (1980). Contributors to this literature have relied upon diﬀerent sur-
veys and diﬀerent deﬁnitions of disability, but have consistently found de-
clines, sometimes sharp and accelerating declines, in disability among the
elderly. Recent work, however, suggests that such declines may not con-
tinue into the future. Lakdawalla, Bhattacharya, and Goldman (2004) ﬁnd
evidence of increasing functional limitation rates in the 1990s in younger
populations. Why these trends are happening, and whether these trends
will continue into the future has important implications for the ﬁnancing
of Medicare.
Manton, Corder, and Stallard (1997) use the 1982, 1984, 1989, and 1994
National Long Term Care Surveys (NLTCS) to investigate trends in the
prevalence of disability in the elderly population. They ﬁnd that the age-
adjusted prevalence of disability in 1994 decreased by 3.6 percent from
1982 (from 24.9 percent to 21.3 percent). Manton and Gu (2001) update
the results of Manton, Corder, and Stallard (1997) using the latest wave of
the NLTCS and conﬁrm a continuing decline in disability among the el-
derly, especially among the oldest age groups. Other authors ﬁnd similar
declines in disability in the 1980s and 1990s using diﬀerent data sets—
Freedman and Martin (1998) ﬁnd declines between 1984 and 1993 in the
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and Reynolds (1997) ﬁnd declines in the 1984 to 1990 Longitudinal Study
of Aging (LSOA) and the 1982 to 1993 National Health Interview Survey
(NHIS). Crimmins, Saito, and Ingegneri (1989) conﬁrm that disability-free
life expectancy increased in the 1980s.
Pardes et al. (1999) and Manton (2003) attribute these improvements in
elderly disability prevalence to developments in medical technology that
enable seniors to delay both disability and death. Manton (2003) suggests
that because the future of medical technology is bright, further improve-
ments can be expected, and these improvements will decrease the demand
for costly care, such as nursing homes, by future elderly cohorts. Manton
and Gu (2001) project that if declines in elderly disability continue at cur-
rent rates, Medicare ﬁnancial insolvency will be delayed signiﬁcantly, per-
haps indeﬁnitely.
Lakdawalla, Bhattacharya, and Goldman (2004) argue that these con-
clusions ignore an important fact. Because disability is typically a long-
lasting health state, an individual who is disabled when near elderly is likely
to be disabled when elderly. Thus, studying disability trends in younger
populations is important for forecasting future trends in disability, which
none of the preceding studies do. Lakdawalla, Bhattacharya, and Gold-
man (2004), using data from the 1984 to 2000 U.S. National Health Inter-
view Surveys (NHIS) to track changes in disability for this population, ﬁnd
that, while disability rates fell slightly for the near elderly population be-
tween 1984 and 1990, they rose dramatically for those under ﬁfty-ﬁve years
old between 1990 and 2000. They attribute a substantial portion of these
trends to rising obesity rates. Further decline in the prevalence of disabil-
ity among incoming Medicare cohorts, they argue, is by no means a certain
prospect.
Bhattacharya et al. (2003) and Lakdawalla et al. (2003a,b) forecast the
implications of cohort-speciﬁc disability trends for future Medicare and
nursing home expenditures, respectively. They ﬁnd that for the next
decade, the documented declines in elderly disability should lead to de-
clines in real per capita Medicare expenditures, holding all else equal.
However, as the younger, more disabled, cohorts age into Medicare, these
trends will reverse themselves. This will lead to increasing per capita Medi-
care expenditures in the decades that follow.
This debate about future disability trends and their implications for
Medicare took place before the passage of Medicare Modernization Act.
None of the forecasts account for the eﬀects of the new drug beneﬁt. In 
addition, with the exception of Moxey et al. (2003), very little work has
been done examining how spending by disabled individuals on prescrip-
tion drugs diﬀers from spending by nondisabled individuals. Moxey et al.
(2003), using 1996 data from the MCBS, ﬁnd that Medicare beneﬁciaries
with “three or more comorbidities and/or diﬃculty with any [activity of
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scription drugs. Beneﬁciaries with “zero comorbidities, no diﬃculty with
[activity of daily living limitations],” by contrast, spend less than $700 per
year on prescription drugs.1 These numbers suggest that the passage of the
Medicare drug beneﬁt will magnify the eﬀect of changing disability trends
on future Medicare ﬁnancing.
8.3 MCBS Pharmaceutical Data
The MCBS is a longitudinal survey covering a nationally representative
sample of around 12,500 Medicare beneﬁciaries per year. Those under
sixty-ﬁve who qualify for Medicare by virtue of their disability are over-
sampled to permit separate analyses of this population, with a sample size
of about 2,000 per year. (Hereafter, we refer to this population as the Dis-
ability Insurance, or DI disabled, because such Medicare recipients must
ﬁrst qualify for Social Security’s DI program.) While the MCBS samples
Medicare beneﬁciaries in nursing homes, we focus in this paper on the non-
institutionalized population because the pharmaceutical data for the two
populations are not directly comparable.2
The MCBS has been conducted annually since 1992, and we use the 1992
to 2001 data here. The MCBS uses a rolling panel design, with individual
respondents being followed for four years and then replaced. All of our
analyses are weighted to be representative of the underlying population of
Medicare beneﬁciaries in each year.
The MCBS collects detail on health status and health care use and costs.
Information on drug usage and expenditures in MCBS resides in two ﬁles,
one for beneﬁciaries living in the community, and a second for beneﬁciar-
ies living in institutions, which we do not use in this paper. The ﬁrst of these
ﬁles, the community ﬁle (RIC_PME) is a prescription level ﬁle. It includes
records for all prescriptions consumed by each beneﬁciary in 2001 while
living in the community, based upon self-reports. In preparation for the in-
terview, respondents are asked to keep a detailed log of their prescriptions,
including reﬁlls. Over-the-counter medications are excluded.
This ﬁle also contains transaction price information for those prescrip-
tions. Transaction prices are sometimes taken as the price reported (30 per-
cent of the records in 2001) to have been paid by a sample respondent. In
the remaining cases, transaction prices are computed by starting with the
average wholesale prices (AWP) for the pharmaceutical product, and dis-
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1. There are some important limitations to the work by Moxey et al. (2003). In particular,
they do not separately examine younger disabled individuals who qualify for Medicare
through the Social Security Disability Insurance program. Furthermore, they do not look at
how the prescription drug expenditures have changed over time.
2. We also exclude end-stage renal disease Medicare patients from our analysis as well for
similar reasons.counting this amount based upon the source paying for the prescription
(for example, Medicaid, Health Maintenance Organization [HMO], Vet-
erans Aﬀairs [VA], Retail, and so on).
Average wholesale prices in the RIC_PME (hereafter PME) ﬁle are im-
puted from to the Medicaid Information System (MIS) using information
on drug name, form, strength and amount, after these ﬁelds are veriﬁed
and modiﬁed to be consistent with drugs descriptions in the First Data-
Bank, which is a comprehensive categorization of pharmaceutical prod-
ucts on the market. The MCBS matches each prescription record to its cor-
responding AWP from the PME ﬁle by as many of the four ﬁelds—drug
name, form, strength, and unit—as possible. When a PME record does not
match all four ﬁelds with a drug available in MIS, an AWP is simulated
from the distribution of scripts in the MIS with as many ﬁelds as matched.
8.4 Methods
Our main aim in this paper is to characterize trends in pharmaceutical
consumption for disabled and nondisabled Medicare populations for the
years t   1992 . . . 2001. The primary outcome variable that we are con-
cerned with is pharmaceutical expenditures for diﬀerent subpopulations
of the Medicare population based upon disability status (say, j), P(t⎪j), as
a fraction of total nonpharmaceutical expenditures, M(t⎪j), plus pharma-
ceutical expenditures:
(1) f(t⎪j)  
As a measure of trends, f(t⎪j) has the advantage of being invariant to in-
ﬂation. Hence, we need not make diﬃcult decisions about which deﬂator—
the Consumer Price Index, the Medical Care Price Index, or some other in-
dex—to use in comparing expenditures in diﬀerent years.
In the remainder of the section, we describe our approach to various
methodological necessities, including deﬁning disability, classifying phar-
maceutical products into therapeutic classes, and the underreporting of
prescription drug use by MCBS respondents.
8.4.1 Deﬁning Disability
Because disability is a primary predictor of Medicare expenditures, we
examine trends for people with and without disabilities. Precision in the
deﬁnition of disability is crucial, and it is particularly important to use 
a deﬁnition that is objective—not subject to manipulation—in order to
avoid moral hazard. In this section, we describe our approach to identify-
ing disabled populations in the MCBS.
For the Medicare population, there are (at least) two conceptually dis-
tinct deﬁnitions of disability, one that applies to the under-sixty-ﬁve popu-
P(t⎪j)
  
P(t⎪j)   M(t⎪j)
Trends in Prescription Drug Use by the Disabled Elderly 287lation, another to the over-sixty-ﬁve population. The ﬁrst deﬁnition is an
administrative deﬁnition. In order for someone under sixty-ﬁve to qualify
for Medicare, that individual must ﬁrst receive Social Security Disability
Insurance (SSDI) payments, and then meet the twenty-four-month quali-
fying period, during which the individual does not work due to the dis-
abling condition. This deﬁnition implies that there may be people who are
younger than age sixty-ﬁve and disabled, in the common use of the term,
yet do not meet the administrative requirements to qualify for Medicare.
However, because we are primarily interested here in Medicare expendi-
tures, we do not attempt to examine such people.
The second deﬁnition focuses instead on the inability to perform a set of
standardized activities (functional limitations) and is assessed in a survey
setting like the MCBS by respondent self-reports. Respondents are asked
a series of questions regarding their diﬃculties in doing six diﬀerent con-
crete activities of daily living (ADL): bathing or showering, dressing, eat-
ing, getting in and out of beds and chairs, walking, and using the toilet. We
divide MCBS respondents over sixty-ﬁve into three groups based upon the
number of these ADLs respondents have diﬃculty performing. The ﬁrst
nondisabled group reports no diﬃculties; the second has problems in either
one or two of these tasks exactly; the third has diﬃculties with three or
more tasks. This is a perfectly standard partitioning of the elderly by their
extent of functional limitations—see Manton and Gu (2001). Many stud-
ies have shown that expected health care expenditures (not including phar-
maceutical expenditures) in the elderly population are least for the nondis-
abled, intermediate for those with one to two ADL limitations, and highest
for those with three to four limitations.3 An individual who qualiﬁes ini-
tially for Medicare through the SSDI program, and then turns sixty-ﬁve, is
considered disabled for our purposes only if that individual exhibits func-
tional limitations.
8.4.2 Tracking Changes in Health and in the Types of 
Drugs Used by Medicare Recipients
Pharmaceutical expenditures for a group of people, such as the disabled,
can change for many reasons. Two primary reasons are changes in the set
of available prescription medications and changes in the composition or
health of the group. To examine these explanations more closely, we exam-
ine what sorts of drugs entail the greatest expenditures for each group.
In table 8A.1 we reproduce a mutually exclusive and exhaustive list of
therapeutic classes to which each drug in the MCBS PME ﬁle is assigned.
This therapeutic classiﬁcation system contains thirty-ﬁve separate classes.
The large number of categories makes it impractical to present trends in
pharmaceutical expenditure for each category. Consequently, we collapse
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3. See, for example, Bhattacharya et al. (2003).this classiﬁcation system into a simpler system, still mutually exclusive and
exhaustive, but consisting of only ﬁve classes: psychotherapeutic agents,
analgesic agents, cardiovascular agents, antiarthritic agents, and all other
drugs. The ﬁrst four classes include several of the most commonly pre-
scribed medications for Medicare patients—see Waldron and Poisal
(1999). The ﬁfth, catch-all category, includes drugs that are unclassiﬁed in
the broader MCBS thirty-ﬁve-class system. These unclassiﬁed drugs make
up a declining proportion of the “all other drugs” category over time—un-
classiﬁed drug products made up over 15 percent of drug spending in 1996
and 1997, before falling oﬀ to around 8 percent in 2000.4
Let P 1(t⎪j)  ...  P 5(t⎪j) represent pharmaceutical expenditures by group j
on drugs in the ﬁve classes we examine, where P(t⎪j)   Σ5
k 1P k(t⎪j). In our
results, we report trends in f1(t⎪j)  ...f5(t⎪j), which are deﬁned analogously
to equation (1):
(2) fk(t⎪j)   for k   1  ...  5
Chronic disease is certainly an important reason for high expenditures on
prescription drugs. There is no reason to suppose that the health of dis-
abled and nondisabled populations in Medicare has remained static over
the past decade. The MCBS asks respondents as series of detailed ques-
tions (“Has your doctor ever told you that you have . . . ?”) about their
health status. To track how changes in the Medicare population have in-
duced changes in use of drugs, for each group j, we identify the individ-
uals in the top 10 percent of the P(t⎪j) distribution. For these top drug
spenders, we plot trends in the prevalence of several of the most common
chronic diseases, including hypertension, arthritis, mental illness, diabetes,
osteoporosis, and Alzheimer’s disease.
8.4.3 MCBS Underreporting of Pharmaceutical Use
To prepare the RIC_PME ﬁle, which contains information on prescrip-
tion drugs for the MCBS, the Center for Medicare and Medicaid Services
(CMS) relies mainly on self-reports by survey respondents. Although re-
spondents are asked in advance to keep track of their use of prescribed
medications, respondents can forget to report some of the medications that
they take. To prevent this problem, respondents are asked to collect all pre-
scription drug containers and insurance receipts during the year before the
interview and to present these materials to the interviewer. The self-reports
are then conﬁrmed against this objective evidence of pharmaceutical
product use. Though there is still a potential for underreporting—for ex-
P k(t⎪j)
  
P(t⎪j)   M(t⎪j)
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4. Among the unclassiﬁed drugs include various emollients and creams that are popular
among people who use Medicare home health services. The decline in this category presum-
ably reﬂects the declining use of home health services after the 1997 Balanced Budget Act,
which cut Medicare payments for such services.ample, respondents may have failed to save containers or receipts—estab-
lishing a corroboration between the self-reports and the objective evidence
lends credence to the MCBS estimates.
To address these sorts of problems, the CMS Information and Methods
Group suggests adjusting MCBS pharmaceutical expenditure data up-
ward by 17 percent—Poisal (2003). Poisal arrives at this ﬁgure by con-
ducting a pharmacy follow-back audit for a subset of the 1999 MCBS 
respondents. We apply this correction factor for underreporting to our 
estimates.
There is an additional source of underreporting error in the MCBS phar-
maceutical data. In addition to the RIC_PME ﬁle, which contains detailed
the information described in the preceding on each prescription, the
MCBS reports total expenditures on prescription drugs, as well as other
medical care expenditures, in a person-level summary ﬁle. We use the
RIC_PME ﬁle to construct our estimates of the numerator in our f(t⎪j)
measures—P(t⎪j)—while we use the person-level summary ﬁle to con-
struct our estimates of the denominators—M(t⎪j)   P(t⎪j).
While the MCBS documentation suggests that the total pharmaceutical
expenditure numbers from these two ﬁles should match, we ﬁnd in practice
that this is not always the case. In nearly every year, between 5 to 6 percent
of the people in the person-level summary ﬁle who have positive drug ex-
penditures do not appear in the PME ﬁle, though they should. This will
tend to understate the numerator in our f(t⎪j) measures.5 Conversely, be-
tween 1 to 2 percent of the people in the PME ﬁle who have prescription
expenditures in a given year do not appear to have any in the in the sum-
mary ﬁle, though they should. This will tend to understate the denomina-
tors in our f(t⎪j) measures. While these two eﬀects tend to oﬀset each other,
our calculations suggest that the net eﬀect is an underestimate of the true
value of f(t⎪j), assuming that anyone reporting pharmaceutical expendi-
tures in the RIC_PME ﬁle should be reporting them in the person-level
summary ﬁle, and vice-versa. Our estimates of pharmaceutical expendi-
ture trends should thus be seen as underestimates.
8.5 Results
In this section, our goal is to characterize how the role that the diﬀerent
types and extent of disability play in determining expenditures on pre-
scription drugs in the Medicare population.
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5. In 1996, this ﬁgure is anomalously high—36 percent of the people in the person-level
summary ﬁle who have positive drug expenditures do not appear in the PME ﬁle. We were un-
able to determine why this is the case. The pharmaceutical expenditure numbers developed
using the 1996 MCBS should thus be seen as severe underestimates.8.5.1 Changes in the Size and Composition of the Medicare Population
We start by examining growth in the population of disabled and nondis-
abled Medicare recipients—Population (t⎪j). Table 8.1 shows these num-
bers for 1992 to 2000, based upon the MCBS population sample weights.
The two biggest net sources of growth in the Medicare population over the
decade were the Medicare DI population, which added over 1.7 million
people, and the nondisabled elderly population, which added over 2.4 mil-
lion people. By contrast, the number of elderly disabled fell slightly over the
period. There were nearly 600,000 fewer elderly with one to two ADL lim-
itations in 2000 than there were in 1992, and about 130,000 fewer with three
or more ADL limitations. These numbers conﬁrm trends reported else-
where in the literature of burgeoning younger disabled populations—Au-
tor and Duggan (2001) and Lakdawalla, Bhattacharya, and Goldman
(2004)—and declining disability among elderly populations—Manton
and Gu (2001).
Table 8.2 explores the Medicare DI population in more detail. It shows
the DI population by primary cause of DI eligibility, as reported in the
MCBS. Mental illness is the modal identiﬁed cause of DI recipiency (15
percent of all DI recipients). With an average age of forty-four, these pa-
tients are also among the youngest recipients. Patients with mental retar-
dation (7.6 percent of DI recipients) are even younger (40.8 years old). 
Disability resulting from chronic diseases and severe acute events such as
strokes (5.3 percent of DI recipients) and cardiovascular disease (10.3 per-
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Table 8.1 Trends in noninstitutionalized Medicare population
Elderly
Disability Diﬃculty Diﬃculty with  Diﬃculty 
Year Insurance with 0 ADLs 1–2 ADLs with  3 ADLs
1992 3,285,364 21,647,427 6,281,249 2,932,333
1993 3,536,864 22,479,300 5,914,561 2,848,153
1994 3,776,145 22,849,250 5,781,001 2,876,014
1995 4,002,487 23,269,384 5,612,604 2,844,031
1996 4,107,449 24,162,911 5,440,830 2,649,575
1997 4,386,421 24,069,791 5,583,173 2,652,202
1998 4,641,815 24,314,895 5,597,334 2,534,695
1999 4,827,507 23,851,277 5,976,560 2,755,146
2000 4,994,876 24,113,225 5,706,425 2,802,296
Change 1992–2000 1,709,512 2,465,798 –574,824 –130,037
Percent change 1992–2000 52 11.3 –9.2 –4.4
Source: 1992–2000 Medicare Current Beneﬁciary Survey.
Note: ADLs   activities of daily living.cent of DI recipients) are nearly as common as mental illness and retarda-
tion as causes of DI recipiency. However, these patients tend to be older
(ﬁfty-ﬁve years old in the case of cardiovascular conditions and ﬁfty years
old in the case of stroke). Similarly, patients with arthritis (7.1 percent of
DI recipients) and with back, spine, or disc injuries (11.3 percent of DI re-
cipients) are, on average, older than ﬁfty years. Given these patterns in the
Medicare DI population, we should expect that use of psychiatric, pain,
and antiarthritic medications are the among the most popular drugs used
by this group.
8.5.2 Trends in Pharmaceutical Expenditures
Figure 8.1 shows trends in per capita nominal pharmaceutical expendi-
tures for disabled and nondisabled Medicare populations. That is, it shows
trends in  (t⎪j)   [P(t⎪j)]/[Population(t⎪j)] for j   DI disabled, elderly
with zero ADL limitations, elderly with one to two ADL limitations, and
elderly with three or more ADL limitations. There is a striking growth in
per capita pharmaceutical expenditures for all of these groups between
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Table 8.2 Primary cause for Social Security Disability Insurance eligibility
Within cause
Cause Percent Mean age Male (%)
Back/spine/disc 11.3 52.3 66.0
Poor eyesight 3.9 49.8 49.9
Poor hearing 1.0 45.2 53.4
Kidney disease 0.6 48.0 56.6
Stroke/seizure disorder 5.3 50.0 61.3
Car/bicycle/train accident 2.6 48.3 68.8
Multiple sclerosis 1.8 49.4 29.4
Muscular dystrophy 0.4 47.8 54.7
Cerebral palsy 0.6 45.9 45.3
Broken bones/hip 1.3 53.5 77.9
Cardiovascular conditions 10.3 55.0 65.1
Cancer 2.5 51.7 49.7
Diabetes 1.7 55.2 63.0
Arthritis 7.1 53.3 51.9
Mental Retardation 7.6 40.8 59.2
Alzheimer’s disease 0.1 55.8 83.5
Mental illness 14.9 44.1 59.3
Osteoporosis 0.3 52.9 32.6
Parkinson’s disease 0.1 47.5 59.2
Emphysema/asthma 1.9 54.8 87.4
Partial paralysis 3.0 55.1 55.3
Loss of limb 0.3 47.6 75.4
Other cause 20.5 50.4 81.3
Source: 1992–1998 Medicare Current Beneﬁciary Survey.1992 and 2001. For example, elderly nondisabled populations spent about
$400 per capita in 1992, and more than $1,100 per capita in 2001. This
group consists of some of the least intensive spenders of prescription
drugs. For the elderly with one to two ADL limitations, pharmaceutical ex-
penditures per capita grew from about $600 in 1992 to almost $1,700 in
2001. In 1992, the elderly with three or more ADL limitations spent the
most on pharmaceutical products—nearly $750 per person. As was the
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Fig. 8.1 Per capita pharmaceutical expenditures by disability category
Source: 1992–2001 Medicare Current Beneﬁciary Survey.case for the other groups, this ﬁgure grew substantially to about $1,950 in
2001. The DI disabled per capita pharmaceutical expenditures grew simi-
larly, but more. In 1992, per capita expenditures were under $700 and rose
to over $2,000 in 2001. The DI disabled now spend the most of all these
groups on prescription drugs.
Figure 8.2 shows total nominal expenditures on prescription drugs for
the groups. As a group, elderly nondisabled spend the most in total on pre-
scription drugs. This is not surprising because this is the largest group of
Medicare beneﬁciaries (see table 8.1). Deﬁne  P j P(2001⎪j) – P(1992⎪j),
294 Jay Bhattacharya, Alan M. Garber, and Thomas MaCurdy
Fig. 8.2 Total nominal pharmaceutical expenditures by disability category
Source: 1992–2001 Medicare Current Beneﬁciary Summary. Popj   Population (2001⎪j) – Population (1992⎪j), and   j    (2001⎪j)
–  (1992⎪j). Then:
(3)  P j    (1992⎪j) Popj   Population (1992⎪j)  j.
Because Population (1992⎪nondisabled) is the largest among the groups,
and  Popnondisabled is also largest, a $1 growth in per capita expenditures for
the nondisabled translates to the largest growth in total expenditures. Al-
though the elderly with three or more ADL limitations spend more per
capita than the elderly with one to two ADL limitations, the greater size of
the latter group means it spends more in total. For both groups, even
though population size declined between 1992 and 2001, total expendi-
tures on prescription drugs as a group rose. Total pharmaceutical expen-
ditures by the DI disabled grew sharply because that group saw both a large
increase in population and per capita expenditure.
Because ﬁgures 8.1 and 8.2 present pharmaceutical expenditures in
nominal dollars, some of the growth in expenditures shown there is due to
inﬂation. Figure 8.3, which presents trends in f(t⎪j), does not have this
problem because both numerator and denominator are measured in nom-
inal dollars. The results from ﬁgure 8.3 are striking. For all four groups,
pharmaceutical expenditures as a percent of total medical expenditures
were largely ﬂat until 1997, after which f(t⎪j) increased sharply.6 The
largest increases in pharmaceutical expenditures were for the DI Medicare
population. For this group, prescription drugs rose between 1992 and 2001
from about 12.5 percent of total medical expenditures to just under 25 per-
cent. The elderly also saw a steep growth in these numbers over this period,
though not quite as steep. The nondisabled elderly went from 11 percent to
about 19 percent; the elderly with one to two ADL limitations went from
about 9.5 percent to 15 percent; and the elderly with three or more ADL
limitations went from under 7 percent to 11 percent. These last two elderly
groups depend more heavily upon inpatient and outpatient medical care
than do the nondisabled elderly and the DI Medicare populations, and this
is reﬂected in their lower positions on the graph. The main point, though,
is that all groups are relying much more heavily on prescription drugs for
their care than they were just a few years ago.
8.5.3 Trends in the Composition of Prescribed Drugs
Figure 8.4 shows the growth in expenditures on prescription drugs in
diﬀerent therapeutic classes. There are ﬁve panels, corresponding to each
class in our simpliﬁed therapeutic class scheme.
Panel A of ﬁgure 8.4 shows trends in expenditures on psychotherapeutic
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6. The biggest changes to Medicare in 1997 came with the passage of the 1997 Balanced
Budget Amendment (BBA). Analyzing the eﬀects of the BBA on pharmaceutical expendi-
tures by the Medicare population is beyond the scope of this paper, but is a topic worthy of
study.agents as a fraction of total medical care expenditures. The DI population
is the big story in this panel—its expenditures on these drugs expanded
from 2 percent of total expenditures to 4 percent. Given the prominence of
mental illness as a primary cause of DI eligibility, the high level of expen-
ditures on psychotherapeutic drugs by this group should not come as a 
surprise, though the increase over the decade is still striking. Meanwhile,
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Fig. 8.3 Pharmaceutical expenditure as a fraction of total expenditure (including
drugs)
Source: 1992–2001 Medicare Current Beneﬁciary Summary.A
Fig. 8.4 Expenditures on prescription drugs in diﬀerent therapeutic classes: A, Ex-
penditures on psychotherapeutic agents as a fraction of total expenditure (including
drugs); B, Expenditures on analgesic agents as a fraction of total expenditure (in-
cluding drugs); C, Expenditures on cardiovascular agents as a fraction of total ex-
penditure (including drugs); D, Expenditures on antiarthritic agents as a fraction of
total expenditure (including drugs); E, Expenditures on all other therapeutic agents
as a fraction of total expenditure (including drugs)
Source: 1992–2001 Medicare Current Beneﬁciary Survey.B
Fig. 8.4 (cont.) Expenditures on prescription drugs in diﬀerent therapeutic classes:
A, Expenditures on psychotherapeutic agents as a fraction of total expenditure (in-
cluding drugs); B, Expenditures on analgesic agents as a fraction of total expendi-
ture (including drugs); C, Expenditures on cardiovascular agents as a fraction of to-
tal expenditure (including drugs); D, Expenditures on antiarthritic agents as a
fraction of total expenditure (including drugs); E, Expenditures on all other thera-
peutic agents as a fraction of total expenditure (including drugs)
Source: 1992–2001 Medicare Current Beneﬁciary Survey.elderly expenditures on these drugs, regardless of the number of ADL lim-
itations, stayed low (about 0.5 percent of total expenditures) and ﬂat over
the period.
Panel B of ﬁgure 8.4 tells a similar story for analgesic agents. These rose
from about 0.5 percent of total expenditures to over 1.5 percent between
1992 and 2001 for the DI population, but stayed ﬂat for the elderly popu-
lation at roughly 0.1 percent to 0.4 percent of total expenditures.
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Fig. 8.4 (cont.) D
Fig. 8.4 (cont.) Expenditures on prescription drugs in diﬀerent therapeutic classes:
A, Expenditures on psychotherapeutic agents as a fraction of total expenditure (in-
cluding drugs); B, Expenditures on analgesic agents as a fraction of total expendi-
ture (including drugs); C, Expenditures on cardiovascular agents as a fraction of to-
tal expenditure (including drugs); D, Expenditures on antiarthritic agents as a
fraction of total expenditure (including drugs); E, Expenditures on all other thera-
peutic agents as a fraction of total expenditure (including drugs)
Source: 1992–2001 Medicare Current Beneﬁciary Survey.Panel C of ﬁgure 8.4 shows that expenditures on cardiovascular drugs
have risen for all groups, DI disabled and elderly alike, unlike analgesics
and psychotherapeutic drugs. The sharpest growth has been among non-
disabled elderly, where expenditures on these drugs grew from 1.9 percent
of total expenditures to 5.4 percent between 1992 and 2001. This propor-
tion grew for other groups as well, but not quite as sharply.
Similarly, panel D of ﬁgure 8.4 shows expenditure growth between 1992
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Fig. 8.4 (cont.) and 2001 for antiarthritic drugs. This time, the change in use of these drugs
seems similar for the four groups. For both cardiovascular and antiar-
thritic drugs, much of the increase in f (t⎪j) took place after 1996—before
then, expenditures on cardiovascular and antiarthritic drugs were ﬂat or
declining. One hypothesis is that the rise in expenditures after 1996 reﬂects
the release into the market of some new and expensive cardiovascular and
antiarthritic drugs, including (the now infamous) COX-2 inhibitors, angio-
tensin receptor blockers, and disease modifying antirheumatic drugs,
though exploring this hypothesis further is beyond our scope.7
Finally, panel E of ﬁgure 8.4 shows changes in f (t⎪j) for all other drugs
between 1992 and 2001. These drugs make up roughly half of the pharma-
ceutical expenditures (that is psychotherapeutic, analgesic, cardiovascu-
lar, and antiarthritic drugs together make up about half of pharmaceutical
expenditures), though this fraction varies from year to year and for the
diﬀerent groups. All of the groups show a similar patter in their expendi-
tures on this catch-all category of drugs. After declines between 1992 and
1996, there are sharp increases in expenditures for all other drugs between
1997 and 2001, though the increases are sharpest for the DI disabled.
8.5.4 Changes in the Disease Prevalence among 
the Top 10 percent of Drug Spenders
Figure 8.5plots trends in the self-reported health status of the highest 10
percent of drug spenders in the four groups. Table 8.3 summarizes these
graphs by reporting changes between 1992 and 2001 in the prevalence 
of these conditions among these high drug spenders. Panels A through F
of ﬁgure 8.5 track changes in the prevalence of hypertension, arthritis,
mental illness, diabetes, osteoporosis, and Alzheimer’s Disease, respectively,
for these high drug spending four groups. We select these conditions to ex-
amine either because they are costly to treat, or because there have been
new pharmaceutical therapies developed to treat them in the 1990s. The
panels are arranged in declining order of average disease prevalence in the
population. Because we are examining only the noninstitutionalized pop-
ulation, the prevalence of some of these diseases (especially Alzheimer’s
disease) appears low.
The most important ﬁnding of ﬁgure 8.5 and table 8.3 is that the most in-
tensive users of prescription drugs in the noninstitutionalized Medicare
population have become signiﬁcantly less healthy between 1992 and 2001.
The prevalence of all of these conditions have risen, sometimes sharply, for
the disabled and nondisabled alike. These prevalence increases were not
evenly divided across groups, though.
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7. In part, the anomalously low expenditures on pharmaceuticals in 1996 can be explained
by mismeasurement, for reasons described in note 5.A
Fig. 8.5 Self-reported health status among top 10 percent of drug spenders: A,
Prevalence of hypertension among top 10 percent of drug spenders; B, Prevalence of
arthritis among top 10 percent of drug spenders; C, Prevalence of mental illness
among top 10 percent of drug spenders; D, Prevalence of diabetes among top 10 per-
cent of drug spenders; E, Prevalence of osteoporosis among top 10 percent of drug
spenders; F, Prevalence of Alzheimer’s disease among top 10 percent of drug
spenders
Source: 1992–2001 Medicare Current Beneﬁciary Survey.B
Fig. 8.5 (cont.) Self-reported health status among top 10 percent of drug spenders:
A, Prevalence of hypertension among top 10 percent of drug spenders; B, Prevalence
of arthritis among top 10 percent of drug spenders; C, Prevalence of mental illness
among top 10 percent of drug spenders; D, Prevalence of diabetes among top 10 per-
cent of drug spenders; E, Prevalence of osteoporosis among top 10 percent of drug
spenders; F, Prevalence of Alzheimer’s disease among top 10 percent of drug
spenders
Source: 1992–2001 Medicare Current Beneﬁciary Survey.Among the high-spending DI population, there has been a remarkably
large and steady increase in the prevalence of mental illness—an increase
of forty-two cases per 100 population in just ten years time. This increase
reﬂects both changes in the composition of the Medicare DI population
over this time period as well as the introduction and dissemination of ef-
fective medications to treat certain psychiatric conditions, like depression
and bipolar disorder. The only other change of any size for this population
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Fig. 8.5 (cont.)D
Fig. 8.5 (cont.) Self-reported health status among top 10 percent of drug spenders:
A, Prevalence of hypertension among top 10 percent of drug spenders; B, Prevalence
of arthritis among top 10 percent of drug spenders; C, Prevalence of mental illness
among top 10 percent of drug spenders; D, Prevalence of diabetes among top 10 per-
cent of drug spenders; E, Prevalence of osteoporosis among top 10 percent of drug
spenders; F, Prevalence of Alzheimer’s disease among top 10 percent of drug
spenders
Source: 1992–2001 Medicare Current Beneﬁciary Survey.is in the prevalence of osteoporosis, which rose by seven cases per 100
people.
Among the high-spending nondisabled elderly population, the preva-
lence of several diseases has substantially increased over this period. Os-
teoporosis prevalence grew by eighteen cases per 100, arthritis prevalence
grew by fourteen cases per 100, diabetes prevalence grew by thirteen cases
per 100, and mental disorders grew by twelve cases per 100. These diseases
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Fig. 8.5 (cont.)F
Fig. 8.5 (cont.) Self-reported health status among top 10 percent of drug spenders:
A, Prevalence of hypertension among top 10 percent of drug spenders; B, Prevalence
of arthritis among top 10 percent of drug spenders; C, Prevalence of mental illness
among top 10 percent of drug spenders; D, Prevalence of diabetes among top 10 per-
cent of drug spenders; E, Prevalence of osteoporosis among top 10 percent of drug
spenders; F, Prevalence of Alzheimer’s disease among top 10 percent of drug
spenders
Source: 1992–2001 Medicare Current Beneﬁciary Survey.suggest that prescription medications have become more important in the
early (that is, before the development of any functional limitation) treat-
ment of chronic diseases.
High-spending elderly with ADL limitations have also had substantial
increases in the prevalence of chronic conditions, including osteoporosis,
arthritis, and hypertension. Unlike the nondisabled elderly, these groups
have not had a large increase in diabetes prevalence. While the nondis-
abled elderly had a large increase in the prevalence of mental disorders,
the increase among these elderly disabled groups has been larger still—
twenty-ﬁve cases per 100 for those with one to two ADLs, and thirty-one
cases per 100 for those with three or more ADLs. Again, this increase 
reﬂects both real changes in the health of these groups and the develop-
ment of new medications. The increase in Alzheimer’s disease prevalence
among these groups has not been as large as the increases in some other
conditions.8
8.6 Conclusions
Though there are many nuances in our results, our most important ﬁnd-
ings can be summarized simply:
• For the disabled and nondisabled, elderly and nonelderly, expendi-
tures on prescription drugs as a fraction of total medical expenditures
grew sharply between 1992 and 2001. Much of the growth took place
between 1996 and 2001.
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8. One important determinant of the community prevalence of Alzheimer’s disease is the
probability of entering a nursing home conditional on having the disease. In recent years, this
probability has been falling—see Lakdawalla et al. (2003a,b). The changes in Alzheimer’s dis-
ease prevalence in the noninstitutionalized population is thus an overestimate in the change
in disease prevalence in the overall population.
Table 8.3 Change in disease prevalence among top 10 percent of drug spenders
(1992–2001; cases in group per 100 noninstitutionalized population)
Elderly
Disability 
Insurance 0 ADLs 1–2 ADLs 3   ADLs
Hypertension  1  6  11  6
Arthritis  1  14  11  6
Mental disorders  42  12  25  31
Diabetes  2  13  4  2
Osteoporosis  7  18  10  6
Alzheimer’s disease  1  1  4  7
Note: ADLs   activities of daily living.• The growth in pharmaceutical expenditures was especially great for
DI Medicare recipients, who were the fastest growing segment of the
Medicare population in the 1990s.
• The DI Medicare population had large increases in expenditures on
all drug categories we examined (psychotherapeutic, analgesic, anti-
arthritic, cardiovascular, and all other drugs), with especially large
increases for psychotherapeutic drugs. The top 10 percent of people in
this group in terms of pharmaceutical expenditures had an astound-
ingly large increase in the prevalence of mental illness, with smaller in-
creases in other chronic diseases.
• The elderly Medicare population had increases between 1992 and
2001 in expenditures for cardiovascular, antiarthritic, and all other
drugs. Among the top 10 percent of elderly drug spenders, with and
without functional limitations, there were moderate increases in the
prevalence of several chronic diseases, including hypertension, arthri-
tis, diabetes, and osteoporosis. Among the top 10 percent of elderly
drug spenders with functional limitations, the prevalence of mental ill-
ness also increased sharply.
These ﬁndings have important implications for future Medicare ﬁnanc-
ing and policy. We brieﬂy explore two related implications here, though
there are certainly others. The ﬁrst implication relates to the costs of the
new Medicare drug beneﬁt. Our results come from the 1990s, long before
the implementation of Medicare Part D. During that period, many Medi-
care recipients had little or no insurance coverage for their prescription
drugs, and hence faced signiﬁcant out-of-pocket payments for them. To
the extent that the new drug beneﬁt reduces the out-of-pocket price paid
by Medicare enrollees, it will further increase demand for prescription
drugs. Hence, all else equal, the increasing trend in prescription drug ex-
penditures we present here underestimate the ﬁnancial exposure faced by
Medicare under the prescription drug plan. Reductions in cost sharing for
drugs should accelerate these trends by increasing moral hazard. Estimat-
ing carefully the eﬀect of Part D cost-sharing on the demand for pharma-
ceutical is thus a vital topic for further research.9
Finally, these ﬁndings reinforce the importance of forecasting disability
rates accurately. If disability prevalence among the elderly continues to de-
cline sharply, then the addition of Part D to Medicare might be ﬁnancially
manageable. If, on the other hand, the increasingly disabled near elderly
age into Medicare in a disabled state, and the set of DI Medicare enrollees
continue to grow, Medicare faces a substantial additional ﬁnancial risk
from the introduction of Part D. Any attempt to forecast future pharma-
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9. A complete forecast would also incorporate the eﬀect of increased use of pharmaceuti-
cals on the demand for other types of medical care, as well as on mortality and morbidity
rates.ceutical expenditure growth without including the disabled population will
result in an underestimate of future growth of pharmaceutical expendi-
tures.
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Central nervous system (CNS) drugs
Contraceptives
Cough and cold preparations
Diagnostic
Diuretics
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Electrolyte, caloric, and ﬂuid replacement
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Comment Jonathan Skinner
There are few analyses of pharmaceutical drug utilization in the general el-
derly population, and most of those are cross-sectional (e.g., Safran et al.
[2005], although see Centers for Medicare and Medicaid Services [CMS]
n.d.). Thus, Bhattacharya, Garber, and MaCurdy should get special credit
for tackling an extremely diﬃcult problem, which is tracking prescription
drug use among the elderly and disabled population between 1992 and
2001. The Medicare Current Beneﬁciary Survey (MCBS) can be extremely
tricky to use as a longitudinal data set, and the fact that their estimates look
reasonable and tell a compelling story is all the more remarkable. For this
alone, the authors deserve applause. Understanding pharmaceutical cost
growth is a particularly important topic, given the future potential of even
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